How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Digital PCR Instrument Market
- By Technology Type: Droplet Digital PCR, Chip-based Digital PCR, Microfluidic Digital PCR, Nanofluidic Digital PCR
- By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Clinical Diagnostics Laboratories, Contract Research Organizations (CROs), Agricultural and Environmental Testing Labs
- By Application: Gene Expression Analysis, Rare Mutation Detection, Copy Number Variation Analysis, Pathogen Detection, Non-invasive Prenatal Testing (NIPT), Liquid Biopsy
- By Product Type: Digital PCR Instruments, Digital PCR Consumables and Reagents, Digital PCR Software
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Droplet Digital PCR leads By Technology Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.166 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.174 →
Full report · locked preview
Everything inside the Digital PCR Instrument Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Technology Type 4
End User 5
Application 6
Product Type 3
Companies profiled
Bio-Rad Laboratories Inc.
Thermo Fisher Scientific Inc.
RainDance Technologies (a Bio-Rad company)
Stilla Technologies
QIAGEN N.V.
JN Medsys
Analytik Jena AG
Fluidigm Corporation
Dawei Biotechnology Co. Ltd.
Abcam plc
Sartorius AG
Biorad Laboratories
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Bio-Rad Laboratories Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Thermo Fisher Scientific Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →RainDance Technologies (a Bio-Rad company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Stilla Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →QIAGEN N.V.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →JN Medsys
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Analytik Jena AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Fluidigm Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Dawei Biotechnology Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Abcam plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sartorius AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Biorad Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →LGC Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Takara Bio Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Formulatrix
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,625M by 2033 · 4.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Droplet Digital PCR51.0
- Chip-based Digital PCR15.8
- Microfluidic Digital PCR18.5
- Nanofluidic Digital PCR14.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,785M → $2,787M · 5.7%
Europe$1,244M → $1,900M · 5.4%
Asia Pacific$1,136M → $1,417M · 2.8%
Latin America$703.1M → $1,071M · 5.4%
Middle East and Africa$540.8M → $846.7M · 5.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.342026
4.342027
4.362028
4.382029
4.392030
4.392031
4.412032
4.422033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Bio-Rad Laboratories Inc.11.8
- Thermo Fisher Scientific Inc.19.4
- RainDance Technologies (a Bio-Rad company)10.0
- Stilla Technologies11.8
- QIAGEN N.V.14.3
- JN Medsys4.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Technology Type31.8%
End User17.6%
Application29.2%
Product Type21.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe23.7
- Asia Pacific17.7
- Latin America13.4
- Middle East and Africa10.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Bio-Rad Laboratories Inc. | 97 | 91 | 82 | 76 | 80 | 96 | 87 |
| Thermo Fisher Scientific Inc. | 92 | 85 | 82 | 92 | 91 | 79 | 87 |
| RainDance Technologies (a Bio-Rad company) | 86 | 73 | 67 | 80 | 82 | 71 | 77 |
| Stilla Technologies | 74 | 75 | 63 | 57 | 71 | 59 | 67 |
| QIAGEN N.V. | 59 | 59 | 53 | 57 | 56 | 69 | 59 |
| JN Medsys | 50 | 63 | 71 | 71 | 63 | 56 | 62 |
| Analytik Jena AG | 59 | 52 | 58 | 64 | 59 | 53 | 58 |
| Fluidigm Corporation | 36 | 49 | 39 | 47 | 41 | 55 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Bio-Rad Laboratories Inc.
- Thermo Fisher Scientific Inc.
- RainDance Technologies (a Bio-Rad company)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories Inc. | ✓ | ✓ | ✓ | ◐ | ◐ | ✓ |
| Thermo Fisher Scientific Inc. | ✓ | ✓ | ✓ | ◐ | ✓ | ✓ |
| RainDance Technologies (a Bio-Rad company) | ✓ | ◐ | ✓ | ◐ | ◐ | − |
| Stilla Technologies | ✓ | ✓ | − | − | − | − |
| QIAGEN N.V. | ◐ | ◐ | ◐ | − | − | ✓ |
| JN Medsys | − | ◐ | − | ◐ | − | − |
| Analytik Jena AG | − | − | ◐ | − | ◐ | − |
| Fluidigm Corporation | − | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Bio-Rad Laboratories Inc.87
2Thermo Fisher Scientific Inc.87
3RainDance Technologies (a Bio-Rad company)77
4Stilla Technologies67
5JN Medsys62
6QIAGEN N.V.59
7Analytik Jena AG58
8Fluidigm Corporation45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Bio-Rad Laboratories Inc.Thermo Fisher Scientific Inc.
Challenger2
Strong scale, closing on the leaders.
RainDance Technologies (a Bio-Rad company)Stilla Technologies
Contender3
Focused players with pockets of strength.
QIAGEN N.V.JN MedsysAnalytik Jena AG
Niche1
Specialists in a single segment or region.
Fluidigm Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Technology Type in North America, then scale across Digital PCR Instrument Market — a $314M beachhead inside a $5.43B market.
Beachhead (SOM)$314Mobtainable near-term
Serviceable (SAM)$1.88Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Droplet Digital PCR
Best fit — highest urgency & budget in Technology Type.
Economic buyer77 fit
Chip-based Digital PCR
Strong fit — clear ROI and a fast path to value.
End user65 fit
Microfluidic Digital PCR
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Technology Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve18%
Marketplaces10%
Positioning & messaging
§GTM 2 · p.194 →For Technology Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Digital PCR Instrument Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified22%
Evaluation11%
Closed-won8%
$11.2KCAC
$41KLTV
3.6:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Digital PCR Instrument Market is a resilient opportunity — $2.05B by 2033, compounding at 5.3%.
TAM · 2025$1.35Btoday
TAM · 2033$2.05Bforecast
CAGR5.3%2027–2033
Cumulative$15.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.05BTotal addressable market
SAM$805MServiceable available market
SOM$161MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.3% CAGR
Demand compounds through 2033, outpacing GDP across Technology Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Technology Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.05BLarge & growingTAM by 2033 at 5.3% CAGR
$805MServiceable nowreachable with today’s model
$161MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.60BBear3.5% CAGR
$2.05BBase5.3% CAGR
$2.63BBull7.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Digital PCR Instrument Market — a $6.77B market by 2033. Plan: grow share from 8.1% to 13.3%.
Market size · 2033$6.77Btotal addressable
Market CAGR11.4%2027–2033
Target share13.3%from 8.1% today
Revenue ambition$900Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.1% | 13.3% | On track |
| Revenue | $600M | $900M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 33.2% | 39.4% | On track |
| Customer retention | 89.0% | 96.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Technology Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Technology Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $101M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Technology Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeAhead
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Digital PCR Instrument Market conversation — a $909M market you can size, segment and defend in minutes.
Market size · 2033$909Mtotal opportunity
Growth3.8%CAGR to 2033
Addressable buyers1,003+accounts in scope
Typical ROI4.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Technology Type
Goal Grow share in Technology Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.7×return on cost, year one
< 4 mopayback period
$61K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Bio-Rad Laboratories Inc.Thermo Fisher Scientific Inc.RainDance Technologies (a Bio-Rad company)Stilla TechnologiesQIAGEN N.V.JN MedsysAnalytik Jena AGFluidigm Corporation+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Digital PCR Instrument Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Digital PCR Instrument Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Allogeneic Stem Cell Therapy Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportDesmopressin Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportAllogeneic Stem Cells Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportDesmopressin Acetate Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportAllogeneic Human Chondrocyte Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportDaunorubicin Hydrochloride (CAS 23541-50-6) Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportAllogeneic Bone Implant Materials Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportAllogeneic Bone Graft Substitutes Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportKidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportAllogeneic Bone Graft Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportCinacalcet Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportCilastatin Sodium Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.